Purpose of review: To describe the recent advances in the pathobiology and treatment of mucus hypersecretion in asthma, a critical factor contributing to airway obstruction, inflammation, and impaired lung function.
Recent findings: Significant progress has been made in understanding how mucin protein regulation, mucus viscosity, and adhesion are affected by cytokine-driven inflammation, especially interleukin-13, and defects in ion transport mechanisms. Advances in imaging techniques, such as multidetector computed tomography (MDCT) and hyperpolarized gas MRI, allow for a more precise assessment of mucus plugging and associated ventilation defects. Emerging therapies, including biologicals targeting type-2 (T2) inflammation, and novel mucolytics aimed at modifying mucus properties and secretion, offer promising effects in reducing mucus in severe asthmatics.
Summary: The growing understanding of mucus biology and the development of advanced imaging and therapeutic strategies could significantly improve the management of mucus-related complications in asthma. By targeting mucus characteristics, these findings support future approaches to reduce airway obstruction, enhance lung function, and improve clinical outcomes in patients with severe asthma. A deeper understanding of the glycobiology of mucus is critical to develop new therapies.
Copyright © 2025 Wolters Kluwer Health, Inc. All rights reserved.